Inactive Instrument

Follicum AB (publ)

Equities

FOLLI

SE0006288270

Biotechnology & Medical Research

Follicum AB Publ Reports Earnings Results for the Fourth Quarter Ended December 31, 2020

February 18, 2021 at 02:45 am EST

Follicum AB publ announced earnings results for the fourth quarter ended December 31, 2020. For the fourth quarter, the company announced operating loss was SEK 11.692 million compared to SEK 11.448 million a year ago. Net loss was SEK 11.643 million compared to SEK 11.412 million a year ago. Basic loss per share from continuing operations was SEK 0.15 compared to SEK 0.17 a year ago.

Latest news about Follicum AB (publ)

Coegin Pharma AS completed the acquisition of Follicum AB.	22-02-06	CI
Follicum AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-03	CI
Follicum AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-18	CI
Coegin Pharma AS agreed to acquire Follicum AB for SEK 35.4 million.	21-09-22	CI
Follicum AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-26	CI
Follicum AB Reports Revised Top-Line Results from the Phase IIa study of FOL-005 for the Treatment of Hair Loss	21-06-24	CI
Follicum AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-20	CI
Follicum AB Announces Executive Changes	21-05-10	CI
Follicum AB Reports Top-Line Results from Phase IIa Study of FOL-005 for Treatment of Hair Loss	21-05-06	CI
Follicum Announces CEO Changes	21-03-25	CI
Follicum AB Establishes New Role as Chief Scientific Officer	21-03-25	CI
Follicum AB Announces New Preclincial Study Confirms Mechanism of Action of its Novel Tissue Repair Peptides	21-03-23	CI
Follicum AB Publ Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	21-02-18	CI
Follicum AB Reports That All Patients Have Completed Treatment with FOL-005 in the Phase II Study Against Hair Loss	21-01-28	CI
Follicum AB Announces All Patients Included in the Ongoing Ase IIa Clinical Study with itits Lead Drug Candidate FOL-005	20-10-08	CI
Follicum AB Enrolls More Than 50% of Patients in Follicum's Phase II Study of FOL-005 for Stimulation of Hair Growth	20-08-18	CI
Follicum Re-Starts Phase II Study with FOL-005 for Stimulation of Hair Growth and Expands the Number of Study Centers	20-06-03	CI
Follicum AB Files International Patent Application Conferring Extended Protection for the Topical Formulation of FOL-005 and Other Peptides	20-05-12	CI
Follicum AB Pauses Recruitment of Patients in Phase II clinical trial of FOL-005 as A Result of the Ongoing COVID-19 Pandemic	20-03-18	CI
Follicum AB Announces Treatment of First Group of Patients Treated in Phase Ii Trial with Fol-005 Cream for Hair Growth Stimulation	20-03-09	CI
Follicum AB Receives Approval from German Medicines Agency and the German Ethics Committee to Start Phase IIa Clinical Study with a Topical Formulation of FOL-005 on Patients with Alopeciacy	20-01-30	CI
Follicum Announces Positive Human Ex Vivo Data from Preclinical Diabetes Studies of New Class of FOL Peptides	19-12-17	CI
Follicum Collaborates with proDERM for Upcoming Phase IIa Clinical Trial on Patients with Hair Loss	19-11-12	CI
Follicum Successfully Completes Toxicology Studies for Upcoming FOL-005 Phase IIa Clinical Trial in Patients with Hair Loss	19-10-21	CI
Follicum AB Receives Approval to Commence Phase IIa Study of Fol-005 Against Hair Loss Approved by the German Medicines Agency	18-02-06	CI

Chart Follicum AB (publ)

Duration

Period

More charts

Company Profile

Follicum AB is a Sweden-based biopharmaceutical company. The Company develops pharmaceutical treatments to control hair growth. It focuses on both drugs to inhibit and stimulate hair growth. The Company's main drug candidate for hair growth inhibition, FOL-005, is based on an endogenous protein. Its drug candidates for hair growth stimulation, are based on an endogenous protein that is broken down by the body.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+2.62%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.39%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.37%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.28%	18.12B
MEDPACE HOLDINGS, INC.	+30.45%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.90%	11.76B
UNITED THERAPEUTICS CORPORATION	+7.78%	11B

Other Biotechnology & Medical Research